BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vijiaratnam N, Foltynie T. Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. Drugs 2020;80:775-96. [PMID: 32382948 DOI: 10.1007/s40265-020-01310-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Kong L, Xi J, Jiang Z, Yu X, Liu H, Wang Z, Agrawal N. Zonisamide’s Efficacy and Safety on Parkinson’s Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/4817488] [Reference Citation Analysis]
2 Di Luca DG, Reyes NGD, Fox SH. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease. Drugs 2022. [PMID: 35841520 DOI: 10.1007/s40265-022-01747-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Teymourian H, Tehrani F, Longardner K, Mahato K, Podhajny T, Moon JM, Kotagiri YG, Sempionatto JR, Litvan I, Wang J. Closing the loop for patients with Parkinson disease: where are we? Nat Rev Neurol 2022. [PMID: 35681103 DOI: 10.1038/s41582-022-00674-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Liu Y, Han J, Guo X, Fang L, Liu T, Pelusi D. Scanning Imaging Study of Patients with Parkinson’s Disease Lower Urinary Tract Dysfunction Based on Linear Equation. Scanning 2022;2022:1-6. [DOI: 10.1155/2022/9506328] [Reference Citation Analysis]
5 Chaudhuri KR, Hand A, Obam F, Belsey J. Cost-effectiveness analysis of the Parkinson's KinetiGraph and clinical assessment in the management of Parkinson's disease. J Med Econ 2022;25:774-82. [PMID: 35593687 DOI: 10.1080/13696998.2022.2080437] [Reference Citation Analysis]
6 Tsuboi Y, Nakamura M, Maruyama H, Matsumoto Y. Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. J Neurol Sci 2021;430:120026. [PMID: 34715471 DOI: 10.1016/j.jns.2021.120026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Singh A, Gupta D, Dhaneria S, Sheth PG. Istradefylline Versus Opicapone for "Off" Episodes in Parkinson's Disease: A Systematic Review and Meta-Analysis. Ann Neurosci 2021;28:65-73. [PMID: 34733056 DOI: 10.1177/09727531211046362] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Raj K, Gupta GD, Singh S. l-Theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson's disease. Drug Chem Toxicol 2021;:1-12. [PMID: 34210222 DOI: 10.1080/01480545.2021.1907909] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Thach A, Sutphin J, Coulter J, Leach C, Pappert E, Mansfield C. Patient Preferences for Treating "OFF" Episodes in Parkinson's Disease: A Discrete Choice Experiment. Patient Prefer Adherence 2021;15:1187-96. [PMID: 34103902 DOI: 10.2147/PPA.S301644] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Vijiaratnam N, Girges C, Auld G, Chau M, Maclagan K, King A, Skene S, Chowdhury K, Hibbert S, Morris H, Limousin P, Athauda D, Carroll CB, Hu MT, Silverdale M, Duncan GW, Chaudhuri R, Lo C, Del Din S, Yarnall AJ, Rochester L, Gibson R, Dickson J, Hunter R, Libri V, Foltynie T. Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study. BMJ Open 2021;11:e047993. [PMID: 34049922 DOI: 10.1136/bmjopen-2020-047993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Girges C, Vijiaratnam N, Athauda D, Auld G, Gandhi S, Foltynie T. The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs Aging 2021;38:355-73. [PMID: 33738783 DOI: 10.1007/s40266-021-00853-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Scott LJ. Opicapone: A Review in Parkinson's Disease. CNS Drugs 2021;35:121-31. [PMID: 33428178 DOI: 10.1007/s40263-020-00778-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Berger AA, Winnick A, Welschmeyer A, Kaneb A, Berardino K, Cornett EM, Kaye AD, Viswanath O, Urits I. Istradefylline to Treat Patients with Parkinson's Disease Experiencing "Off" Episodes: A Comprehensive Review. Neurol Int 2020;12:109-29. [PMID: 33302331 DOI: 10.3390/neurolint12030017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Vijiaratnam N, Wirth T, Morris HR. Revisiting the assessment of tremor: clinical review. Br J Gen Pract 2020;70:611-4. [PMID: 33243918 DOI: 10.3399/bjgp20X713849] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 2020;91:795-808. [PMID: 32576618 DOI: 10.1136/jnnp-2019-322338] [Cited by in Crossref: 136] [Cited by in F6Publishing: 116] [Article Influence: 68.0] [Reference Citation Analysis]